Early impact of cross-sex steroids on body composition and metabolic profile in young transgender subjects

Author(s):  
Pierre Consolandi ◽  
Veronique Pascal ◽  
Caroline Samhani ◽  
Clement Larose ◽  
Philip Bohme ◽  
...  
2015 ◽  
Vol 40 (7) ◽  
pp. 695-702 ◽  
Author(s):  
Eve Normandin ◽  
Eric Doucet ◽  
Rémi Rabasa-Lhoret ◽  
Martin Brochu

Obesity is a heterogeneous condition, since the metabolic profile may differ greatly from one individual to another. The objective of this study was to compare the effect of a 6-month diet-induced weight loss program on body composition and the metabolic profile in obese individuals displaying different obesity phenotypes. Secondary analyses were done on 129 obese (% body fat: 46% ± 4%) postmenopausal women (age: 57 ± 4 years). Outcome measures included body composition, body fat distribution, glucose homeostasis, fasting lipids, and blood pressure. Obesity phenotypes were determined based on lean body mass (LBM) index (LBMI = LBM/height2) and visceral fat (VF) accumulation, as follows: 1, lower VF and lower LBMI (n = 35); 2, lower VF and higher LBMI (n = 19); 3, higher VF and lower LBMI (n = 14); and 4, higher VF and higher LBMI (n = 61). All groups had significantly improved measures of body composition after the intervention (P < 0.0001). Greater decreases in LBM and LBMI were observed in the higher LBMI groups than in the lower LBMI groups (P < 0.0001). Similarly, decreases in VF were greater in the higher VF groups than in the lower VF groups (P < 0.05). Overall, fasting insulin levels and glucose disposal improved following the intervention, with higher LBMI groups showing a trend for greater improvements (P = 0.06 and 0.07, respectively). Overall, no difference was observed among the different obesity phenotypes regarding improvements in the metabolic profile in response to weight loss. Individuals displaying higher VF or higher LBMI at baseline experienced significantly greater decreases for these variables after the intervention.


2020 ◽  
Vol 8 (1) ◽  
pp. e001303
Author(s):  
Toru Kusakabe ◽  
Shigefumi Yokota ◽  
Mika Shimizu ◽  
Takayuki Inoue ◽  
Masashi Tanaka ◽  
...  

IntroductionTreatment using sodium-glucose cotransporter (SGLT) 2 inhibitor and low-carbohydrate diet (LCD) for obesity and type 2 diabetes are similar in terms of carbohydrate limitation. However, their mechanisms of action differ, and the effects on the body remain unclear. We investigated the effects of SGLT2 inhibitor and LCD on body composition and metabolic profile using the db/db mouse model for obesity and type 2 diabetes.Research design and methodsEight-week-old male db/db mice were divided into four groups: mice receiving normal diet and vehicle or canagliflozin (Cana) administration and mice receiving LCD and vehicle or Cana administration for 8 weeks. Consumed calories were adjusted to be equal among the groups.ResultsBoth Cana administration and LCD feeding resulted in significant weight gain. Cana administration significantly decreased plasma glucose levels and increased plasma insulin levels with preservation of pancreatic β cells. However, LCD feeding did not improve plasma glucose levels but deteriorated insulin sensitivity. LCD feeding significantly reduced liver weight and hepatic triglyceride content; these effects were not observed with Cana administration. Combined treatment with LCD did not lead to an additive increase in blood β-ketone levels.ConclusionsSGLT2 inhibitors and LCD exert differential effects on the body. Their combined use may achieve better metabolic improvements in obesity and type 2 diabetes.


Author(s):  
Jordana Carolina Marques Godinho-Mota ◽  
Joao Felipe Mota ◽  
Larissa Vaz Gonçalves ◽  
Leonardo Ribeiro Soares ◽  
Raquel Machado Schincaglia ◽  
...  

2014 ◽  
Vol 37 (6) ◽  
pp. 693-702 ◽  
Author(s):  
Ashraf S. Gorgey ◽  
David R. Dolbow ◽  
James D. Dolbow ◽  
Refka K. Khalil ◽  
Camilo Castillo ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document